Insider Buying: Caribou Biosciences, Inc. (NASDAQ:CRBU) CFO Purchases $24,651.20 in Stock

Caribou Biosciences, Inc. (NASDAQ:CRBU) CFO Sriram Ryali purchased 17,360 shares of the stock in a transaction that occurred on Wednesday, January 29th. The shares were bought at an average cost of $1.42 per share, for a total transaction of $24,651.20. Following the acquisition, the chief financial officer now owns 17,360 shares of the company’s stock, valued at approximately $24,651.20. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Caribou Biosciences Stock Down 2.2 %

Shares of Caribou Biosciences stock traded down $0.03 during trading on Thursday, hitting $1.31. 1,625,759 shares of the company were exchanged, compared to its average volume of 1,531,784. The firm has a 50 day moving average price of $1.79 and a 200 day moving average price of $1.99. The stock has a market capitalization of $118.62 million, a price-to-earnings ratio of -0.79 and a beta of 2.34. Caribou Biosciences, Inc. has a fifty-two week low of $1.30 and a fifty-two week high of $8.33.

Caribou Biosciences (NASDAQ:CRBU) last announced its earnings results on Wednesday, November 6th. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.06. Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%. The firm had revenue of $2.02 million during the quarter, compared to the consensus estimate of $3.37 million. Analysts predict that Caribou Biosciences, Inc. will post -1.64 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have issued reports on CRBU shares. Bank of America dropped their price objective on shares of Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. Citigroup decreased their target price on shares of Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday, November 26th. Finally, HC Wainwright reiterated a “buy” rating and issued a $9.00 price target on shares of Caribou Biosciences in a report on Friday, November 15th. Five analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $10.33.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in CRBU. Erste Asset Management GmbH purchased a new position in Caribou Biosciences during the third quarter worth about $28,000. AQR Capital Management LLC acquired a new stake in shares of Caribou Biosciences in the second quarter worth approximately $30,000. China Universal Asset Management Co. Ltd. grew its holdings in Caribou Biosciences by 63.8% in the third quarter. China Universal Asset Management Co. Ltd. now owns 17,380 shares of the company’s stock valued at $34,000 after purchasing an additional 6,768 shares during the period. Intech Investment Management LLC acquired a new position in Caribou Biosciences during the third quarter worth approximately $43,000. Finally, Point72 DIFC Ltd raised its stake in Caribou Biosciences by 389.4% during the second quarter. Point72 DIFC Ltd now owns 30,157 shares of the company’s stock worth $49,000 after purchasing an additional 23,995 shares during the period. Hedge funds and other institutional investors own 77.51% of the company’s stock.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.